Up­dat­ed: US se­lects first 10 drugs sub­ject to Medicare price ne­go­ti­a­tions

The US on Tues­day un­veiled the first 10 drugs that will be sub­ject to price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act, in­clud­ing sev­er­al sur­pris­ing ad­di­tions that may face com­pe­ti­tion from gener­ics be­fore the ne­go­ti­a­tions start in 2026.

In to­tal, the drugs racked up more than $50 bil­lion in Medicare Part D spend­ing from May 2022 to June of this year, and in­clude three prod­ucts from John­son & John­son as well as block­busters from Bris­tol My­ers Squibb, Eli Lil­ly, Mer­ck and oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER